The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CHEMBL56252     (2S)-2-[[(2S)-2-amino-3- phenyl...

Synonyms: SureCN1738816, SureCN4546522, CHEBI:44034, CHEBI:187376, CTK0G0632, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of C11602

 

High impact information on C11602

  • Similarly, 32- to 64-fold reductions in MICs in the presence of MC-207,110 were observed for strains with overexpressed efflux pumps and various target mutations that confer resistance to levofloxacin (e.g., gyrA and parC) [3].
  • METHODS: Two wild-type Campylobacter jejuni strains and their isogenic cmeB mutants were used to determine the susceptibilities of the strains to various bile salts in the presence of EPI MC-207,110 or MC-04,124 [1].
  • Investigation of 21 Campylobacter isolates from various origins further showed that the EPI MC-207,110 decreased bile resistance in all isolates [1].
  • Up to 50% (18/36) of in vitro mutants displayed a positive efflux phenotype when nalidixic acid was combined with MC-207,110, while 6% (2/36) showed the phenotype when exposed to nalidixic acid and reserpine [4].
  • Examination of 57 Campylobacter isolates from various origins further demonstrated that MC-207,110 decreased the MICs of erythromycin (2- to 512-fold) in all isolates [5].
 

Chemical compound and disease context of C11602

 

Gene context of C11602

  • Together, these findings indicate that EPI MC-207,110 inhibits the function of CmeABC efflux pump and potentiates the activity of antibiotics against Campylobacter [5].
 

Analytical, diagnostic and therapeutic context of C11602

References

  1. Effect of efflux pump inhibitors on bile resistance and in vivo colonization of Campylobacter jejuni. Lin, J., Martinez, A. J. Antimicrob. Chemother. (2006) [Pubmed]
  2. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Coban, A.Y., Ekinci, B., Durupinar, B. Chemotherapy. (2004) [Pubmed]
  3. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Lomovskaya, O., Warren, M.S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., Leger, R., Hecker, S., Watkins, W., Hoshino, K., Ishida, H., Lee, V.J. Antimicrob. Agents Chemother. (2001) [Pubmed]
  4. Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains. Valdezate, S., Vindel, A., Saéz-Nieto, J.A., Baquero, F., Cantón, R. J. Antimicrob. Chemother. (2005) [Pubmed]
  5. Effect of an Efflux Pump Inhibitor on the Function of the Multidrug Efflux Pump CmeABC and Antimicrobial Resistance in Campylobacter. Martinez, A., Lin, J. Foodborne Pathog. Dis. (2006) [Pubmed]
 
WikiGenes - Universities